This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on ISI (5)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Diabetic Retinopathy  • Macular Disorders  • Cardiovascular System  • Articles for Residents  • Cardiovascular Disease/ Myocardial Infarction  • Drug Therapy  • Drug Therapy, Other  • Alert me on articles by topic  Social Bookmarking   What's this?

Lucy Q. Shen, MD; Angie Child, MD; Griffin M. Weber, MD, PhD; Judah Folkman, MD; Lloyd Paul Aiello, MD, PhD

Arch Ophthalmol. 2008;126(6):793-799.

Objective  To evaluate whether rosiglitazone maleate, an oral peroxisome-proliferating activated receptor agonist and oral insulin sensitizing agent with potential antiangiogenic activity, delays onset of proliferative diabetic retinopathy (PDR).

Methods  Longitudinal medical record review of all patients treated with rosiglitazone receiving both medical and ophthalmic care at the Joslin Diabetes Center from May 1, 2002, to May 31, 2003 (N = 124), and matched control patients not taking a glitazone drug (N = 158). The mean duration of follow-up was 2.8 years (range, 0.3-9.0 years).

Results  Baseline characteristics and final hemoglobin A_1c values (7.6% and 7.8%, respectively) were similar in the rosiglitazone and control groups (P = .10). In eyes with severe nonproliferative diabetic retinopathy at baseline (rosiglitazone group, 14 eyes; control group, 24 eyes), progression to PDR over 3 years occurred in 19.2% in the rosiglitazone group and 47.4% in the control group, representing a 59% relative risk reduction (Wilcoxon, P = .045; log-rank, P = .059). Fewer eyes in the rosiglitazone group experienced 3 or more lines of visual acuity loss (P = .03). The incidence of diabetic macular edema was similar in both groups.

Conclusions  Rosiglitazone may delay the onset of PDR, possibly because of its antiangiogenic activity. Future clinical investigations should consider analysis of this potential benefit along with ongoing evaluation of potential cardiac risk in studies where the risk-benefit profiles are deemed appropriate.

Author Affiliations: Harvard Medical School (Drs Shen, Child, Weber, Folkman, and Aiello), Beth Israel Deaconess Medical Center (Dr Weber), Children's Hospital Boston (Dr Folkman), and Beetham Eye Institute and Eye Research Section, Joslin Diabetes Center (Dr Aiello), Boston, Massachusetts; and Jules Stein Eye Institute, University of California–Los Angeles (Dr Shen). Died January 14, 2008.

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Challenges in Understanding Diabetic Embryopathy
Loeken
Diabetes 2008;57:3187-3188.
FULL TEXT